OIE Reference Laboratory Reports Activities

Activities in 2021

This report has been submitted : 2021-12-21 14:28:39

Name of disease (or topic) for which you are a designated OIE Reference Laboratory:	Foot and mouth disease
Address of laboratory:	Av. Sir. Alexander Fleming 1653 Martínez (1640) Buenos Aires ARGENTINA
Tel.:	+54-11 48.36.19.95
Fax:	+54-11 48.36.19.95
E-mail address:	dilab@senasa.gob.ar
Website:	
Name (including Title) of Head of Laboratory (Responsible Official):	Dr. Ana Nicola General Director of General Direction of Laboratory and Technicaal Control. Dr. Rodrigo Balzano Director of Animal Laboratory Dr. Sebastian Otero Coordinator of Animal Health Dr. Ana Taffarel Head of Ruminant Diseases department
Name (including Title and Position) of OIE Reference Expert:	Dr. Sabrina Galdo Novo (responsible for the information in this form. Waiting for OIE evaluation)
Which of the following defines your laboratory? Check all that apply:	Governmental

ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in OIE Manual (Yes/No)	Total number of test performed last year	
Indirect diagnostic tests		Nationally	Internationally
NSP ELISA 3 ABC	YES	11298	0
EITB	YES	574	0
SP LP ELISA	YES	21946	0
AGID	YES	192	0
VNT	YES	7846	0
Direct diagnostic tests		Nationally	Internationally
VIRAL ISOLATION	YES	98	0
TYPING ELISA FOR ANTIGEN DETECTION	YES	22	0
COMPLEMENT FIXATION	YES	2558	0
Q RT PCR	YES	48	0
CONVENTIONAL PCR	YES	30	0
SEQUENCING	YES	70	0

ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards.
To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE?

No

3. Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries?

Yes

Type of reagent available	Related diagnostic test	Produced/ provide	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	No. of recipient OIE Member Countries	Region of recipients
inactivated fmdv antigen	for immunization of guinea pig for elaboration of hiperinmune sera elisa in house production formulation of exprinmental vaccines	20360	20360 ml	0	0	☐Africa ☒Americas ☐Asia and Pacific ☐Europe ☐Middle East
guinea pig hiperimmune sera	complement fixation for antigenic characterization, identy and inocuity determination in vaccines	527	507 ml	20 ml	1	☐Africa ☒Americas ☐Asia and Pacific ☐Europe ☐Middle East
guinea pig complement	complement fixation for antigenic characterization, identy and inocuity determination in vaccines	377	377 ml	0	0	☐Africa ☒Americas ☐Asia and Pacific ☐Europe ☐Middle East
fmdv strain epithelia of reference	for in vivo challenge test or referene adapted strain	46	46 gr	0	0	☐Africa ☒Americas ☐Asia and Pacific ☐Europe ☐Middle East

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to OIE Member Countries?

No

ToR 3: To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases

6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?

No

7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?

No

ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries

8. Did your laboratory carry out diagnostic testing for other OIE Member Countries?

No

9. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?

Yes

Name of the OIE Member Country receiving a technical consultancy	Purpose	How the advice was provided
QATAR	GENERAL INFORMATION ON VACCINE CONTROL, VACCINATION STRATEGIES AND VIRAL ISOLATION AND CHARACTERIZATION	OFFICIAL VISIT
VIETNAM	INFORMATION ON FMDV VACCINES AND R1 INTERPRETATION	INFORMAL COMMUNICATION

ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations

10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?

Yes

Title of the study	Duration	Purpose of the study	Partners (Institutions)	OIE Member Countries involved other than your country
STUDY ON IMPROVEMENT OF FOOT-AND MOUTH DISEASE VACCINE NATIONAL ASSAY	2019-2021	establish the correlation between virus neutralization and antigen mass of different vaccine formulations	APQA - Republic of Korea SENASA - Argentina	KOREA (REP. OF)
FOOT AND MOUTH DISEASE VIRAL FIELD STRAIN CHARACTERIZATION	2021-ONGOING	Identification and characterization of circulationg strains in order to generate information for the control or fmdv in Vietnm	RAHO 6-DAH-Vietnam SENASA-Argentina	VIETNAM

ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases

11. Did your Laboratory collect epizootiological data relevant to international disease control?

Yes

If the answer is yes, please provide details of the data collected:
Genetic and antigenic characterization of FMDV field strains.

12. Did your laboratory disseminate epizootiological data that had been processed and analysed?

Yes

If the answer is yes, please provide details of the data collected:
Sequences published in NBCI nucleotide. Preliminary resultes published at VI Global Foot-and-Mouth Disease Research Alliance (GFRA) Scientific Meeting. Draft manuscripts to be send for evaluation for publication.

13. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category)

a) Articles published in peer-reviewed journals: 0
Do to COVID -19 circulation part of the staff of the laboratory was dedicated to covid 19 diagnosis. This temporal reasignation of personnel implied limited activities in relation to research.

b) International conferences: 2

VI Global Foot-and-Mouth Disease Research Alliance (GFRA) Scientific Meeting (1-3, november 2021).
Global Foot-and-Mouth Disease Research Alliance (GFRA) REGIONAL AMERICAS (March 10 th, 2021).

c) National conferences: 0
Do to COVID -19 circulation part of the staff of the laboratory was dedicated to covid 19 diagnosis. This temporal reasignation of personnel implied limited activities in relation to research.

d) Other:
(Provide website address or link to appropriate information) 0

ToR 7: To provide scientific and technical training for personnel from OIE Member Countries
To recommend the prescribed and alternative tests or vaccines as OIE Standards

14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

Yes

a) Technical visits: 1
b) Seminars: 0
c) Hands-on training courses: 0
d) Internships (>1 month): 0

Type of technical training provided (a, b, c or d)	Country of origin of the expert(s) provided with training	No. participants from the corresponding country
a	QATAR	4

ToR 8: To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned

15. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)
ISO 17025 ACREDITED	Certificado de acreditación - ISO 17025-2017.pdf

16. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
3 ABC NSP ELISA	ORGANIMO ARGENTINO DE ACREDITACION

17. Does your laboratory maintain a “biorisk management system” for the pathogen and the disease concerned?

Yes

(See Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Chapter 1.1.4)

ToR 9: To organise and participate in scientific meetings on behalf of the OIE

18. Did your laboratory organise scientific meetings on behalf of the OIE?

No

19. Did your laboratory participate in scientific meetings on behalf of the OIE?

No

ToR 10: To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results

20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

Yes

21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?

Yes

Purpose of the proficiency tests: [1]	Role of your Reference Laboratory (organiser/ participant)	No. participants	Participating OIE Ref. Labs/ organising OIE Ref. Lab.
Centro Panamericano de Fiebre Aftosa y Salud Pública Veterinaria, de la Organización Panamericana de la Salud/Organización Mundial de la Salud (PANAFTOSA/SPV-OPS/OMS), dando seguimiento a su programa regular de ensayo de proficiencia (comparación interlaboratorio) en salud animal para la red de laboratorios de América Latina, correspondiente al año 2021 (PEP-2021)	PARTICIPANT	NOT PUBLISHED YET	ORGANIZER: PANAFTOSA-PAHO-BRAZIL PARTICIPANTS: RESULTS ARE ON EVALUATION AND HAVE NOT BEEN PUBLISHED YET
2021 Foot-and-Mouth Disease (FMD) Proficiency Tes□ng Scheme (PTS).	PARTICIPANT	NOT PUBLISHED YET	ORGANIZER: PIRBRIGHT PARTICIPANTS: PTS TRAIL HAS ARRIVE ON DEC 16TH TO AIRPORT SO THE PTS TRIAL IS BEING EXECUTED

[1] *validation of a diagnostic protocol: specify the test; quality control of vaccines: specify the vaccine type, etc.*

22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Yes

Title of the project or contract	Scope	Name(s) of relevant OIE Reference Laboratories
STUDY ON IMPROVEMENT OF FOOT-AND MOUTH DISEASE VACCINE NATIONAL ASSAY	establish the correlation between virus neutralization and antigen mass of different vaccine formulations.	APQA - REP OF KOREA

ToR 11: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results

23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?

No

Note: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at: http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing see point 1.3

ToR 12: To place expert consultants at the disposal of the OIE

24. Did your laboratory place expert consultants at the disposal of the OIE?

No

25. Additional comments regarding your report:

Do to COVID -19 circulation part of the staff of the laboratory was dedicated to covid 19 diagnosis. This temporal reasignation of personnel implied limited activities in relation to research. International activity was limited and national/internal activities were prioritized.